必治妥施貴寶報告骨髓瘤治療試驗取得成功
Bristol Myers Squibb reports successful trial for myeloma treatment
Updated at: September 26, 2026 at 02:50 AM
百時美施貴寶(Bristol Myers Squibb, BMS)在對抗多發性骨髓瘤(multiple myeloma)這項複雜的血癌上，正取得重大進展。
Bristol Myers Squibb (BMS) is making significant strides in the fight against multiple myeloma, a complex blood cancer.
該公司近期分享了來自多項臨床試驗的樂觀數據，突顯出其向次世代療法轉型的策略。
The company recently shared promising data from several clinical trials, highlighting a strategic shift toward next-generation therapies.
在第3期EXCALIBER-RRMM試驗中，使用含ZENBEXUS治療方案的病患，其臨床成效較標準療法有顯著提升。
In the Phase 3 EXCALIBER-RRMM trial, patients using a regimen containing ZENBEXUS showed much better clinical outcomes compared to standard treatments.
美國食品藥物管理局(FDA)近期給予該方案加速核准，對先前已接受過治療的患者而言，是一個重要的里程碑。
The U.S.
透過標靶GPRC5D，arlo-cel為那些已窮盡現有治療選項的患者提供了新的出路。
The Phase 2 QUINTESSENTIAL trial revealed that its investigational CAR T-cell therapy, arlo-cel, achieved strong response rates in patients who were previously resistant to other treatments.
隨著舊藥因學名藥競爭而導致營收下滑，這些創新療法對該公司的未來至關重要。
By targeting GPRC5D, arlo-cel offers a new path for those who have exhausted existing options.
透過CELMoD平台與精密複雜的CAR T技術，BMS成功地更新了其血液科產品組合，以應對治療抗藥性。
As revenue from older medications declines due to generic competition, these innovative treatments are essential to the company’s future.
